Zacks Investment Research on MSN1d
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
One of the ways diabetes can affect the body is by overstimulating the sweat glands. Because of this, it's harder to maintain a steady internal body temperature. Extreme fluctuations in blood sugar ...
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...
Profits and losses for petrelintide and the petrelintide/CT-388 combination will be shared on a 50:50 basis in the U.S. and Europe, while Zealand will be eligible to receive tiered double-digit ...
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...
Investor's Business Daily on MSN2d
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 BillionRoche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative ...
The global AI in Remote Patient Monitoring Market, valued at US$1551.8 million in 2023, is forecasted to grow at a robust CAGR of 27.5%, reaching ...
The global AI in Remote Patient Monitoring Market, valued at US$1551.8 million in 2023, is forecasted to grow at a robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback